Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Joanna Dobroszycki, Jacobo Abadi, Andrew A Wiznia & Michael G Rosenberg. (2011) Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients. Adolescent Health, Medicine and Therapeutics 2, pages 85-93.
Read now
Read now
Cameron Wolfe & Charles Hicks. (2009) Profile of darunavir in the management of treatment-experienced HIV patients. HIV/AIDS - Research and Palliative Care 1, pages 13-21.
Read now
Read now
Articles from other publishers (21)
Ean Spielvogel, Sook-Kyung Lee, Shuntai Zhou, Gordon J Lockbaum, Mina Henes, Amy Sondgeroth, Klajdi Kosovrasti, Ellen A Nalivaika, Akbar Ali, Nese Kurt Yilmaz, Celia A Schiffer & Ronald Swanstrom. (2023) Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance. eLife 12.
Crossref
Crossref
Taťána Majerová & Jan Konvalinka. (2022) Viral proteases as therapeutic targets. Molecular Aspects of Medicine 88, pages 101159.
Crossref
Crossref
Yaser Shabanpour, Sharareh Sajjadi, Esmaeil Behmard, Parviz Abdolmaleki & Amir Homayoun Keihan. (2022) The structural, dynamic, and thermodynamic basis of darunavir resistance of a heavily mutated HIV-1 protease using molecular dynamics simulation. Frontiers in Molecular Biosciences 9.
Crossref
Crossref
Karina Pikalyova, Alexey Orlov, Arkadii Lin, Olga Tarasova, MarcouGilles Marcou, Dragos Horvath, Vladimir Poroikov & Alexandre Varnek. (2022) HIV-1 drug resistance profiling using amino acid sequence space cartography. Bioinformatics 38:8, pages 2307-2314.
Crossref
Crossref
Yogesh Kumar Verma, Ranjan Verma, Nishant Tyagi, Amanpreet Behl, Subodh Kumar & Gurudutta U. Gangenahalli. (2020) COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy. Stem Cell Reviews and Reports 17:1, pages 113-131.
Crossref
Crossref
Sabyasachi Biswal, Sumanta Mondal & Prasenjit Mondal. (2021) A novel ultra performance liquid chromatography-PDA method development and validation for darunavir in bulk and its application to marketed dosage form. Journal of Pharmacy And Bioallied Sciences 13:1, pages 69.
Crossref
Crossref
Manisha Yadav, Swasti Dhagat & J. Satya Eswari. (2020) Emerging strategies on in silico drug development against COVID-19: challenges and opportunities. European Journal of Pharmaceutical Sciences 155, pages 105522.
Crossref
Crossref
Haydar Bulut, Shin-ichiro Hattori, Hiromi Aoki-Ogata, Hironori Hayashi, Debananda Das, Manabu Aoki, David A. Davis, Kalapala Venkateswara Rao, Prasanth R. Nyalapatla, Arun K. Ghosh & Hiroaki Mitsuya. (2020) Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity. Scientific Reports 10:1.
Crossref
Crossref
E. Pontiki, A. Peperidou, I. Fotopoulos & D. Hadjipavlou-Litina. 2020. Cancer-Leading Proteases. Cancer-Leading Proteases
165
182
.
Vassilios Paparizos, Varvara Vasalou & Sofia Kourkounti. (2019) Dolutegravir with boosted darunavir as treatment simplification for treatment-experienced HIV patients with multiple mutations. International Journal of STD & AIDS 30:12, pages 1214-1215.
Crossref
Crossref
Elżbieta Jabłonowska, Ewa Siwak, Monika Bociąga-Jasik, Jacek Gąsiorowski, Anna Kalinowska, Ewa Firląg Burkacka, Kamila Wójcik-Cichy, Anna Piątek, Iwona Cielniak & Andrzej Horban. (2019) Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients. PLOS ONE 14:1, pages e0210476.
Crossref
Crossref
Ayodeji A. Agbowuro, Wilhelmina M. Huston, Allan B. Gamble & Joel D. A. Tyndall. (2018) Proteases and protease inhibitors in infectious diseases. Medicinal Research Reviews 38:4, pages 1295-1331.
Crossref
Crossref
Magda SwedrowskaShirin JamshidiAbhinav KumarCharles KellyKhondaker Miraz Rahman & Ben Forbes. (2017)
In Silico
and
in Vitro
Screening for P-Glycoprotein Interaction with Tenofovir, Darunavir, and Dapivirine: An Antiretroviral Drug Combination for Topical Prevention of Colorectal HIV Transmission
. Molecular Pharmaceutics 14:8, pages 2660-2669.
Crossref
Crossref
Tatevik Balayan, Hacsi Horvath & George W. Rutherford. (2017) Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review. AIDS Research and Treatment 2017, pages 1-9.
Crossref
Crossref
Masaaki Nakashima, Hirotaka Ode, Koji Suzuki, Masayuki Fujino, Masami Maejima, Yuki Kimura, Takashi Masaoka, Junko Hattori, Masakazu Matsuda, Atsuko Hachiya, Yoshiyuki Yokomaku, Atsuo Suzuki, Nobuhisa Watanabe, Wataru Sugiura & Yasumasa Iwatani. (2016) Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance. Frontiers in Microbiology 7.
Crossref
Crossref
Nico Holmstock, Frank J. Gonzalez, Myriam Baes, Pieter Annaert & Patrick Augustijns. (2013) PXR/CYP3A4-Humanized Mice for Studying Drug–Drug Interactions Involving Intestinal P-Glycoprotein. Molecular Pharmaceutics 10:3, pages 1056-1062.
Crossref
Crossref
Richard BethellJoseph SchererMyriam WitvrouwAgnes PaquetEoin CoakleyDavid Hall. (2012) Short Communication: Phenotypic Protease Inhibitor Resistance and Cross-Resistance in the Clinic from 2006 to 2008 and Mutational Prevalences in HIV from Patients with Discordant Tipranavir and Darunavir Susceptibility Phenotypes. AIDS Research and Human Retroviruses 28:9, pages 1019-1024.
Crossref
Crossref
J Young, AU Scherrer, HF Günthard, M Opravil, S Yerly, J Böni, M Rickenbach, CA Fux, M Cavassini, E Bernasconi, P Vernazza, B Hirschel, M Battegay & HC Bucher. (2011) Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV Medicine 12:5, pages 299-307.
Crossref
Crossref
Nico Holmstock, Raf Mols, Pieter Annaert & Patrick Augustijns. (2010) In Situ Intestinal Perfusion in Knockout Mice Demonstrates Inhibition of Intestinal P-Glycoprotein by Ritonavir Causing Increased Darunavir Absorption. Drug Metabolism and Disposition 38:9, pages 1407-1410.
Crossref
Crossref
Barun Bhhatarai , Rajni Garg & Paola Gramatica. (2010) Are Mechanistic and Statistical QSAR Approaches Really Different? MLR Studies on 158 Cycloalkyl-Pyranones. Molecular Informatics 29:6-7, pages 511-522.
Crossref
Crossref
Ying-Jie Wang, Philip M. McKenna, Renee Hrin, Peter Felock, Meiqing Lu, Kristen G. Jones, Craig A. Coburn, Jay A. Grobler, Daria J. Hazuda, Michael D. Miller & Ming-Tain Lai. (2010) Assessment of the susceptibility of mutant HIV-1 to antiviral agents. Journal of Virological Methods 165:2, pages 230-237.
Crossref
Crossref